Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

When the study ended, weight loss did not plateau, suggesting that patients may continue to lose weight, Lilly said.

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Following the company’s announcement that its diabetes and weight-loss drug helped patients lose up to 16 pounds over 40 ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Despite worries about an economic slowdown, Netflix continues to prove itself to be a recession-resistant stock.

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its other GLP-1 products.

Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application ...